Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
163. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L,<br />
Trusk P, Hill J, Harris J, Spector NL 2006 A model of acquired autoresistance<br />
to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent<br />
its onset in breast cancer. Proc Natl Acad Sci U S A 103:7795-800<br />
164. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L,<br />
Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ<br />
2001 First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a<br />
preliminary report. Eur J Cancer 37 Suppl 1:S25-9<br />
165. Albain K, Elledge R, Gradishar WJ, Hayes A, Rowinsky EK, Hudis C,<br />
Pusztai L, Tripathy D, Modi S, Rubi S 2002 Open-label phase II multicenter<br />
trial of ZD1839 (Iressa) in patients with advanced breast cancer. Breast Cancer<br />
Research and Treatment 76:A20<br />
166. Baselga J, Albanelli J, Ruiz A, Lluch A, Gascon P, Gonzales S, Guillan V,<br />
Sauleda S, Averbuch SD, Rojo F 2003 Phase II and tumor pharmacodynamic<br />
study of gefitinib in patients with advanced breast cancer. Proceedings of the<br />
American Society of Clinical Oncology 22:A24<br />
167. Robertson JFR, Gutteridge E, Cheung KL, Owers R, Koehler M, Hamilton<br />
L, Gee JMW, Nicholson RI 2003 Gefitinib (ZD1839) is active in acquired<br />
tamoxifen-resistant oestrogen receptor positive and <strong>ER</strong>-negative breast cancer:<br />
results from a phase II study. Proceedings of the American Society of Clinical<br />
Oncology 22:A23<br />
168. Dancey JE, Freidlin B 2003 Targeting epidermal growth factor receptor--are we<br />
missing the mark? Lancet 362:62-4<br />
66
Change language